During the past decade, Hanson Clinical Research Center conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hanson Clinical Research Center" #1 sponsor was "Boehringer Ingelheim" with 1 trials, followed by "Eli Lilly and Company" with 1 trials sponsored, "Mylan Inc." with 1 trials sponsored, "Takeda" with 1 trials sponsored and "Teijin America, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hanson Clinical Research Center" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)" with 1 trials as a collaborator, "Mylan GmbH" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Hanson Clinical Research Center" are "Chronic Kidney Disease" (1 trials), "Diabetes" (1 trials), "Diabetes Mellitus, Type 1" (1 trials), "Diabetic Kidney Disease" (1 trials) and "Hypoparathyroidism" (1 trials). Many other conditions were trialed in "Hanson Clinical Research Center" in a lesser frequency.

Most popular intervention types in "Hanson Clinical Research Center" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Empagliflozin" (1 trials), "FlexPen NovoLog®" (1 trials), "Insulin Degludec" (1 trials), "Insulin Efsitora Alfa" (1 trials) and "MYL-1601D Product" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hanson Clinical Research Center" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Hanson Clinical Research Center". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Hanson Clinical Research Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hanson Clinical Research Center, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".